A $7.25 billion class action settlement meant to resolve claims that Monsanto’s Roundup products caused cancer in people has received preliminary approval from a Missouri court, lawyers confirmed on ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...

Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024--2032. Growth is underpinned by ...

The Saturday event, hosted by juniors Tasha McMaster and Westie Davidson, will take place at Resin Gallery in Hermosa Beach.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.Acalabrutinib (Calquence, AstraZeneca) tablets ...